ramucirumab

View Patient Information

A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-VEGFR-2 fully human monoclonal antibody IMC-1121B monoclonal antibody HGS-ETR2
US brand name:	Cyramza
Code name:	IMC-1121B LY3009806
Chemical structure:	immunoglobulin G1, anti-(human vascular endothelial growth factor receptor type VEGFR-2 extracellular domain) (human monoclonal IMC-1121B γ-chain), disulfide with human monoclonal IMC-1121B κ-chain, dimer immunoglobulin G1, anti-(vascular endothelial growth factor receptor 2 (EC 2.7.10.1 or protein-tyrosine kinase receptor Flk-1 or CD309 antigen) extracellular domain); human monoclonal IMC-1121B γ1 heavy chain (219-214')-disulfide with human monoclonal IMC-1121B κ light chain (225-225'':228-228'')-bisdisulfide dimer

ramucirumab

Search NCI's Drug Dictionary